Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Choroidal Neovascularization | 7 | 2020 | 35 | 2.460 |
Why?
|
| Macular Degeneration | 4 | 2020 | 75 | 1.880 |
Why?
|
| CD59 Antigens | 2 | 2017 | 30 | 1.050 |
Why?
|
| Inflammation | 2 | 2020 | 1030 | 0.900 |
Why?
|
| Lasers | 3 | 2017 | 61 | 0.820 |
Why?
|
| Complement Pathway, Alternative | 3 | 2019 | 69 | 0.770 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 1293 | 0.740 |
Why?
|
| Geographic Atrophy | 1 | 2019 | 5 | 0.690 |
Why?
|
| Choroid | 2 | 2016 | 22 | 0.640 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2019 | 155 | 0.620 |
Why?
|
| Medicare | 1 | 2019 | 316 | 0.580 |
Why?
|
| Complement System Proteins | 2 | 2019 | 135 | 0.570 |
Why?
|
| Receptors, Complement 3d | 1 | 2017 | 45 | 0.570 |
Why?
|
| Complement Inactivating Agents | 1 | 2017 | 56 | 0.550 |
Why?
|
| Complement Factor B | 1 | 2015 | 19 | 0.500 |
Why?
|
| Chemokines | 1 | 2014 | 119 | 0.470 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2014 | 20 | 0.470 |
Why?
|
| Retinal Pigment Epithelium | 5 | 2020 | 145 | 0.460 |
Why?
|
| Endothelial Cells | 1 | 2017 | 384 | 0.460 |
Why?
|
| RNA | 1 | 2014 | 171 | 0.460 |
Why?
|
| Organic Anion Transporters | 2 | 2010 | 5 | 0.440 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1663 | 0.440 |
Why?
|
| Mice, Inbred C57BL | 6 | 2020 | 2791 | 0.410 |
Why?
|
| Mice | 10 | 2020 | 8474 | 0.390 |
Why?
|
| Sertoli Cells | 1 | 2010 | 4 | 0.370 |
Why?
|
| Disease Models, Animal | 6 | 2020 | 2550 | 0.370 |
Why?
|
| Tomography, Optical Coherence | 2 | 2020 | 88 | 0.300 |
Why?
|
| Animals | 10 | 2020 | 20880 | 0.270 |
Why?
|
| Receptor, Anaphylatoxin C5a | 2 | 2019 | 20 | 0.200 |
Why?
|
| Arthritis, Experimental | 1 | 2020 | 38 | 0.190 |
Why?
|
| Exudates and Transudates | 1 | 2019 | 25 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 492 | 0.170 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 85 | 0.170 |
Why?
|
| Antirheumatic Agents | 1 | 2019 | 58 | 0.170 |
Why?
|
| Receptors, Complement | 1 | 2019 | 58 | 0.160 |
Why?
|
| Estrone | 2 | 2010 | 9 | 0.160 |
Why?
|
| Electroretinography | 2 | 2016 | 122 | 0.160 |
Why?
|
| Regeneration | 1 | 2019 | 105 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 209 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2019 | 714 | 0.150 |
Why?
|
| Injections, Intraperitoneal | 1 | 2017 | 89 | 0.150 |
Why?
|
| Databases, Factual | 1 | 2019 | 621 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2016 | 8 | 0.140 |
Why?
|
| Mice, Knockout | 2 | 2019 | 1692 | 0.140 |
Why?
|
| Complement C5a | 1 | 2016 | 15 | 0.140 |
Why?
|
| Smoke | 1 | 2016 | 46 | 0.130 |
Why?
|
| Male | 5 | 2020 | 37283 | 0.130 |
Why?
|
| Th17 Cells | 1 | 2016 | 116 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 376 | 0.120 |
Why?
|
| Comorbidity | 1 | 2019 | 1425 | 0.120 |
Why?
|
| Prevalence | 1 | 2019 | 1609 | 0.120 |
Why?
|
| Retina | 1 | 2016 | 252 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 266 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 507 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3256 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.110 |
Why?
|
| CHO Cells | 2 | 2010 | 161 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2016 | 506 | 0.110 |
Why?
|
| Cricetinae | 2 | 2010 | 262 | 0.110 |
Why?
|
| Female | 3 | 2020 | 38021 | 0.100 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 1033 | 0.100 |
Why?
|
| Genetic Therapy | 1 | 2014 | 291 | 0.100 |
Why?
|
| Phenotype | 1 | 2014 | 946 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2798 | 0.100 |
Why?
|
| Spermatids | 1 | 2010 | 1 | 0.090 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2010 | 1 | 0.090 |
Why?
|
| Blood-Testis Barrier | 1 | 2010 | 2 | 0.090 |
Why?
|
| Leydig Cells | 1 | 2010 | 5 | 0.090 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2010 | 9 | 0.090 |
Why?
|
| Microdissection | 1 | 2010 | 15 | 0.090 |
Why?
|
| Cricetulus | 1 | 2010 | 98 | 0.090 |
Why?
|
| Cytokines | 1 | 2014 | 866 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 4843 | 0.090 |
Why?
|
| Substrate Specificity | 1 | 2010 | 234 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2673 | 0.090 |
Why?
|
| Risk Factors | 1 | 2019 | 5720 | 0.080 |
Why?
|
| Kinetics | 1 | 2010 | 1047 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 710 | 0.080 |
Why?
|
| United States | 1 | 2019 | 7338 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2019 | 7268 | 0.070 |
Why?
|
| Humans | 3 | 2019 | 68549 | 0.060 |
Why?
|
| Aged | 1 | 2019 | 14842 | 0.060 |
Why?
|
| Light Coagulation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 46 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 37 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2016 | 351 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 215 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2016 | 62 | 0.030 |
Why?
|
| Spleen | 1 | 2016 | 301 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2016 | 156 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2016 | 236 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 770 | 0.030 |
Why?
|
| DNA | 1 | 2016 | 597 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 630 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 1752 | 0.030 |
Why?
|
| Ochratoxins | 1 | 2006 | 1 | 0.020 |
Why?
|
| Uricosuric Agents | 1 | 2006 | 1 | 0.020 |
Why?
|
| p-Aminohippuric Acid | 1 | 2006 | 3 | 0.020 |
Why?
|
| Penicillin G | 1 | 2006 | 8 | 0.020 |
Why?
|
| Probenecid | 1 | 2006 | 10 | 0.020 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 2006 | 2 | 0.020 |
Why?
|
| Salicylates | 1 | 2006 | 22 | 0.020 |
Why?
|
| Herbicides | 1 | 2006 | 24 | 0.020 |
Why?
|
| GABA Modulators | 1 | 2006 | 26 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2006 | 60 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 72 | 0.020 |
Why?
|
| Biological Transport | 1 | 2006 | 210 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 2006 | 137 | 0.020 |
Why?
|
| Transfection | 1 | 2006 | 782 | 0.010 |
Why?
|